-
Mashup Score: 5STAMPEDE (part 1): A new era for prostate cancer research with Max Parmar & Nick James - 8 month(s) ago
STAMPEDE is a long-running trial in advanced prostate cancer, in which nearly 12,000 men have taken part. Thanks to its multi-arm multi-stage platform design, STAMPEDE has tested many different treatm
Source: soundcloud.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Gerhardt Attard joins Ashley Ross in discussing an ancillary study of the STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone. The addition of abiraterone acetate and prednisolone to ADT is the standard of care for advanced prostate cancer (metastatic, M1 and high-risk…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
An ancillary study of the #STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced #ProstateCancer starting ADT +/- abiraterone acetate and prednisolone. #WatchNow > https://t.co/2NgQkmnH7Q @AttardLab @ashleyrossmdphd @Decipher_VCYT @Veracyte https://t.co/LyHRGzUIyB
-
-
Mashup Score: 5
The STAMPEDE trial presents clear evidence that abiraterone benefits people living with prostate cancer both at the early stages and once the cancer has already spread.
Source: VimeoCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Dr. Craig Jones discusses clinical fracture incidence in mHSPC - Uroweb - 10 month(s) ago
In this podcast, Prof. Igor Tsaur (DE), chief editor of the UROONCO PCa editorial board talks with Mr. Craig Jones (GB), from Salford Royal and Christie Hospitals, about his recent presentation at AUA2023, “Clinical fracture incidence in metastatic hormone-sensitive prostate cancer (mHSPC).”
Categories: Latest Headlines, UrologyTweet
-
Mashup Score: 9The Uromigos • A podcast on Spotify for Podcasters - 10 month(s) ago
Broadcasting the latest developments in GU cancer
Source: Spotify for PodcastersCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 4The Uromigos • A podcast on Spotify for Podcasters - 10 month(s) ago
Broadcasting the latest developments in GU cancer
Source: Spotify for PodcastersCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 2The Uromigos • A podcast on Spotify for Podcasters - 10 month(s) ago
Broadcasting the latest developments in GU cancer
Source: Spotify for PodcastersCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2
AUA 2023 addition of zoledronic acid to ADT with or without docetaxel in the STAMPEDE platform, metastatic hormone sensitive prostate cancer (mHSPC), ADT ± docetaxel ± zoledronic acid.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Clinical fracture incidence in #mHSPC & risk-reduction following the addition of zoledronic acid to ADT w/ or w/o docetaxel: long-term results of two P3 trials in the #STAMPEDE platform protocol - Craig Jones, MBChB @TheChristieNHS > https://t.co/UameSkzez2 @zklaassen_md #AUA23 https://t.co/2LcDABSLwM
-
-
Mashup Score: 0
Marina Parry and Gerhardt Attard join Alicia Morgans in discussing two key studies from the STAMPEDE trial platform, including “Comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for metastatic hormone-sensitive prostate cancer (mHSPC) starting ADT: overall survival (OS) results of 2 randomized Phase III trials from the STAMPEDE…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
Gerhardt Attard joins Ashley Ross in discussing an ancillary study of the STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone. The addition of abiraterone acetate and prednisolone to ADT is the standard of care for advanced prostate cancer (metastatic, M1 and high-risk…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
An ancillary study of the #STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced #ProstateCancer starting ADT +/- abiraterone acetate and prednisolone. #WatchNow > https://t.co/2NgQkmnH7Q @AttardLab @ashleyrossmdphd @Decipher_VCYT @Veracyte https://t.co/XZHzV2rpn6
-
🎧Tune in to listen to the latest episode of the Trial Talk #Podcast (@MRCCTU)🎙️ This is the first part in a new mini-series on the #STAMPEDE clinical trial that features @Prof_Nick_James talking about what made this #ProstateCancer study a success: https://t.co/4ksGMszdxb